Research programme: autoimmune and inflammatory disorder therapies - Sienna Biopharmaceuticals

Drug Profile

Research programme: autoimmune and inflammatory disorder therapies - Sienna Biopharmaceuticals

Alternative Names: CT637; CT802

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Creabilis Therapeutics
  • Class
  • Mechanism of Action High mobility group protein modulators; Toll-like receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation; Plaque psoriasis; Rheumatoid arthritis; Skin disorders

Most Recent Events

  • 06 Dec 2016 Creabilis Therapeutics has been acquired by Sienna Biopharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Italy
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Plaque-psoriasis in Italy (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top